AAIC 2025 Lecanemab Preserves Memory Over 4 Years in Early AD Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a ...

Alert FDA Approves Zongertinib for HER2-Mutated NSCLC Approval followed priority review and was based on response rates and duration of response demonstrated in the phase 1b Beamion LUNG-1 trial.